Evidence map›Paper›PMID 35518717›Full record

ArticleFrontiers in chemistry2022

Phthalimide Analogs Enhance Genotoxicity of Cyclophosphamide and Inhibit Its Associated Hypoxia.

Amira M Gamal-Eldeen, Hussein S Agwa, Magdy A-H Zahran, Bassem M Raafat, Sherien M El-Daly, Hamsa J Banjer, Mazen M Almehmadi, Afaf Alharthi, Nahed M Hawsawi, Fayez Althobaiti and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 59% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Amira M Gamal-EldeenClinical Laboratory Sciences Department, College of Applied Medical Sciences, Taif University, Taif, Saudi Arabia.
Hussein S AgwaResearch & Development Department, Pharco B International Company for Pharmaceutical Industries, Borg El-Arab, Alexandria, Egypt.
Magdy A-H ZahranChemistry Department, Faculty of Science, Menoufiya University, Menoufiya, Egypt.
Bassem M RaafatRadiological Sciences Department, College of Applied Medical Sciences, Taif University, Taif, Saudi Arabia.
Sherien M El-DalyMedical Biochemistry Department, National Research Centre, Cairo, Egypt.
Hamsa J BanjerClinical Laboratory Sciences Department, College of Applied Medical Sciences, Taif University, Taif, Saudi Arabia.
Mazen M AlmehmadiClinical Laboratory Sciences Department, College of Applied Medical Sciences, Taif University, Taif, Saudi Arabia.
Afaf AlharthiClinical Laboratory Sciences Department, College of Applied Medical Sciences, Taif University, Taif, Saudi Arabia.
Nahed M HawsawiClinical Laboratory Sciences Department, College of Applied Medical Sciences, Taif University, Taif, Saudi Arabia.
Fayez AlthobaitiHigh Altitude Research Center, Prince Sultan Medical Complex, Taif University, Taif, Saudi Arabia.
Mona A M Abo-ZeidCancer Biology and Genetics Laboratory, Centre of Excellence for Advanced Sciences, National Research Centre, Cairo, Egypt.
Taif University · SANational Research Centre · EGMenoufia University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cyclophosphamide (CP) is a mutagen that is used in cancer chemotherapy, due to its genotoxicity and as an immunosuppressive agent

Indexed as

cyclophosphamidegenotoxicityhypoxiaphthalimidethalidomide

Identifiers

PMID35518717
PMCPMC9065290
OpenAlexW4224234150

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.